GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Ind-Swift Laboratories Ltd

Ind-Swift Laboratories: Preferential Issue Warrants Fully Utilised

FUNDRAISE ● No Immediate Change LOW RISK
📅 Filed on BSE: 03 Nov 2026, 02:47 PM IST  ·  BSE ID: d15c0d36-d057-4f5f-8283-ce425ea8a034
View Original BSE Filing (PDF)
💡
In Simple Terms
The company confirmed all money raised from selling special warrants has now been spent as planned.
🤖 AI Summary
  • Ind-Swift Labs fully utilized Rs. 3.77 crore proceeds by September 30, 2026.
  • Funds raised were from a preferential issue of 2,60,00,000 fully convertible warrants.
  • This marks the final Monitoring Agency report for the preferential issue.
  • Proceeds utilization was reviewed by the Audit Committee and Board of Directors.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Funds raised through Preferential Issue
Rs. 314.60 crore
Number of Fully Convertible Warrants
2,60,00,000
Balance unutilized proceeds as on September 30, 2026
Rs. 3.77 crore
Period ended
September 30, 2026
🏢 How This Affects the Company
💰
Financial Impact
All proceeds from the preferential issue are now fully utilized, concluding the monitoring period for the funds raised.
⚠️
Risk Impact
The completion of fund utilization reduces any immediate financial reporting or compliance risks associated with unspent funds.
👥 What This Means For Shareholders
✅
Action Required
No action is required by shareholders regarding this monitoring agency report.
👤
Who Is Affected
All shareholders are informed about the conclusion of the fund utilization process for the preferential issue.
🔍
Management Signal
Management's adherence to fund utilization plans and timely reporting signals operational compliance and transparency.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Next quarterly results to confirm ongoing operational performance.
Future announcements regarding deployment of capital for growth initiatives.
Any new fund-raising activities planned by the company.
LOW RISK Filing confirms completion of fund utilization as per SEBI regulations.
💡 Investor Takeaway
Ind-Swift Laboratories has fully utilized Rs. 3.77 crore of funds raised from 2,60,00,000 preferential issue warrants as of September 30, 2026.
⚖️ Strengths & Concerns

✅ Positives

  • All allocated funds from the preferential issue of 2,60,00,000 warrants have been fully utilized.
  • The company has successfully completed the utilization of Rs. 3.77 crore in Q2 FY27, marking finality.
📅 Company Track Record
Previous filings show Ind-Swift Laboratories' board considered fundraising on July 7, 2026, and has also completed ESOP share allotments.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is the total amount raised by Ind-Swift Laboratories through the preferential issue?
Ind-Swift Laboratories raised an aggregate amount of Rs. 314.60 crore through the preferential issue of fully convertible warrants.
When were the funds raised through preferential issue fully utilized?
All proceeds were fully utilized by the quarter ended September 30, 2026, with the balance Rs. 3.77 crore used in Q2 FY27.
What does the Monitoring Agency Report for September 30, 2026 signify?
The report signifies that all proceeds from the preferential issue have been fully utilized, marking it as the final report.
How many fully convertible warrants were issued by Ind-Swift Laboratories?
Ind-Swift Laboratories issued 2,60,00,000 fully convertible warrants as part of the preferential issue.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.